gbp510
Vaccineexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jan 20, 2021 (NCT04742738)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05501522 | Phase 3 | Nov 30, 2022 | Coalition for Epidemic Preparedness Innovations, GlaxoSmithKline, International Vaccine Institute, SK Bioscience Co., Ltd. |
| NCT05175950 | Phase 2 | Jan 31, 2022 | Government of Korea, Korea University |
| NCT05007951 | Phase 3 | Aug 30, 2021 | Coalition for Epidemic Preparedness Innovations, GlaxoSmithKline, International Vaccine Institute, Korea University, SK Bioscience Co., Ltd. |
| NCT04750343 | Phase 1/Phase 2 (Phase 2) | Feb 3, 2021 | Coalition for Epidemic Preparedness Innovations, GlaxoSmithKline, Korea University, SK Bioscience Co., Ltd. |
| NCT04742738 | Phase 1/Phase 2 (Phase 2) | Jan 20, 2021 | Coalition for Epidemic Preparedness Innovations, Korea University, SK Bioscience Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 4 | 0 | 2 | 2021 |
| Korea University | Academic/Hospital | 4 | 1 | 2 | 2021 |
| SK Bioscience Co., Ltd. | For profit | 4 | 4 | 2 | 2021 |
| GlaxoSmithKline | For profit | 3 | 0 | 2 | 2021 |
| International Vaccine Institute | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Government of Korea | Government | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1